Journal of the advanced practitioner in oncology最新文献

Cyclophosphamide remains a critical component to haploidentical transplant conditioning regimens. Post-transplant cyclophosphamide (PTCy) emerged as an effective component of graft-vs.-host disease (GVHD) prophylaxis in the nonmyeloablative haploidentical bone marrow transplant setting. The relative ease of administration compared with ex vivo manipulations and efficacy in reducing GVHD has led to increasing PTCy use in transplant centers around the world. The role of PTCy has expanded to haploidentical transplantation with myeloablative conditioning regimens and peripheral blood progenitor cells as the donor source. Moreover, encouraging results in GVHD management have been shown with the use of PTCy alone or in combination with other immunosuppressives in the human leukocyte antigen-matched donor setting. The toxicity profile of cyclophosphamide varies extensively depending on dose, duration, overall drug exposure, and, potentially, pharmacogenetics. This review highlights the pharmacology, pharmacokinetics, and toxic effects of cyclophosphamide and offers practical guidance for clinical application in the post-transplant setting. We summarize data on the management of high-dose cyclophosphamide toxicities and provide insights into the pharmacogenetic implications on drug efficacy and safety data.

Background: Oncology patients have tremendous symptom burden both physically and emotionally. Palliative care (PC) improves quality of life and prevents suffering. Advance care planning (ACP) empowers patients to articulate goals of their care. New guidelines call for palliative care to be provided and chemotherapy avoided the last 2 weeks of life. The American Society of Clinical Oncology (ASCO) recommends integrating palliative care within the oncology setting to achieve these outcomes. However, the best mode to provide this care remains unclear. A nurse practitioner/physician assistant (NP/PA)-based model from within the oncology clinic is a potential option.

Methods: A program evaluation was done to determine the effectiveness of the "My Choices, My Wishes" NP/PA-led program.

Results: From 2012 to 2018, the number of patients receiving PC/ACP visits increased from 2.6% to 19.4%. The percentage of patients receiving chemotherapy in the last 14 days of life decreased from 12.5% to 7.14%. The number of advance care directives completed increased from 17.5% to 37.5%.

Conclusion: This program was an effective way to provide PC/ACP for oncology patients. We still need to understand why patients pursue chemotherapy at the end of life. It is necessary to improve our communication techniques with patients and families in order to guarantee high-quality, high-value care.

Patients with comorbid mental health and substance use disorders are at greater risk for mortality and have higher cancer care costs. At JADPRO Live Virtual 2021, Lisa W. Goldstone, MS, PharmD, BCPS, BCPP, talked through general considerations in the oncology setting for persons with comorbid mental health or substance use disorders, strategies for recognizing when patients with new or preexisting mental health symptoms or disorders may benefit from treatment and/or referral, and first and second-line pharmacotherapy options.

At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy. Dr. Fadol's presentation discussed identification of the most common cardiotoxicities associated with cancer therapy, clinical considerations related to common oncologic treatments with potential cardiotoxicity that may impact cancer treatment decisions, and the management of common cardiovascular issues in patients with cancer.